The PE firms are eyeing 30-40% stake in the semiconductor services company at a valuation of around $300 million, the people ...

"We are introducing Wegovy (injectable Semaglutide 2.4 mg) this year, which offers full therapeutic strengths of semaglutide ...

The Novo Group Companies , Novo Nordisk A/S and Novonesis ... with several new investments and the decision to open our third Asia office in Mumbai, India, in 2025. Asia Investments deployed ...

Legal battle over Novo Nordisk's semaglutide drug in India, with DRL, raises concerns over patent infringement and drug ...

Novo Holdings ... Kutay said the company would focus this year on expanding its presence in Asia, with the opening of an office in Mumbai, India, following significant investments it already ...

COPENHAGEN (Reuters) - Wegovy-maker Novo Nordisk ousted CEO Lars Fruergaard Jorgensen on Friday over concerns the company is losing its first-mover advantage in the highly competitive obesity drug ...